FPR2 is a therapeutic target in lung cancer

FPR2是肺癌的治疗靶点

• 批准号: nhmrc : 1142013
• 负责人: A/Pr Daniel Steinfort
• 金额: $ 60.72万
• 依托单位: RMIT University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/fpr2-therapeutic-target-lung-cancer/1319623
• 关键词: FPR2; therapeutic; target; lung; cancer

Lung cancer remains the biggest cause of cancer related deaths and chronic smoking is the major risk factor. We have recently demonstrated that a protein termed SAA contributes to damaging inflammation in chronic smokers that develop emphysema through activation of a receptor called FPR2. We will determine whether naturally derived products termed pro-resolving mediators that target this same FPR2 receptor will prove to be a novel and effective treatment for lung cancer.

肺癌仍然是癌症相关死亡的最大原因，而长期吸烟是主要的危险因素。我们最近证明，一种名为SAA的蛋白质通过激活一种名为FPR2的受体，有助于慢性吸烟者患上肺气肿的破坏性炎症。我们将确定以同一FPR2受体为靶点的被称为促分解介体的天然衍生产品是否将被证明是一种新的、有效的肺癌治疗方法。